文献速递皮肤肿瘤

talimogene laherparepvec联合伊匹木单抗对比伊匹木单抗单药治疗晚期不可切除黑色素瘤患者的经济学评价

Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.
PubMed 文献 · JAMA Dermatol · 2019-01-01

基于2期试验数据,采用2状态马尔可夫模型(无进展生存 vs 进展或死亡)和ORR分析,从美国支付方视角(2017年美元)评价talimogene laherparepvec联合伊匹木单抗对比伊匹木单抗单药治疗晚期不可切除黑色素瘤的经济性。联合组费用494983美元,单药组132950美元,ICER为每PFS生命年2129606美元,ICUR为每PFS质量调整生命年2262706美元;每多1例客观缓解的ICER为1629019美元。结论认为该金额可能超出支付方通常愿意支付的范围。

要点

  • 联合组费用494983美元,单药组132950美元,差值362033美元。
  • ICER为每PFS生命年2129606美元,ICUR为每PFS质量调整生命年2262706美元。
  • 每多1例客观缓解的ICER为1629019美元。

核心结论

  • talimogene laherparepvec联合伊匹木单抗在人群层面相对伊匹木单抗单药不提供经济上有利的治疗选择,但不排除对该方案可能适用的个体患者进行治疗。

研究设计与样本

  • 基于2期试验数据,采用2状态马尔可夫模型(无进展生存 vs 进展或死亡)进行PFS成本效果和成本效用分析,并针对ORR进行每1例额外患者达到客观缓解的增量成本效果分析。
  • 研究基于美国支付方视角(2017年美元),对象为晚期不可切除黑色素瘤患者。
  • 主要结局为PFS生命年和PFS质量调整生命年,估计相应ICER和ICUR,并估计每1例额外患者(每100例治疗患者中)达到客观缓解的ICER,基础分析通过敏感性分析验证。

主要发现

  • PFS分析中,talimogene laherparepvec联合伊匹木单抗组费用494983美元,伊匹木单抗单药组132950美元,联合组较单药组高362033美元。
  • ICER为每PFS生命年2129606美元,ICUR为每PFS质量调整生命年2262706美元。
  • 概率敏感性分析得到ICER为每PFS生命年1481208美元,ICUR为每PFS质量调整生命年1683191美元。
  • 在支付意愿阈值为每PFS质量调整生命年1683191美元时,联合治疗具有成本效果的概率为50%。
  • ORR分析中,联合组费用474904美元,单药组132810美元,差值342094美元,每1例额外患者达到客观缓解的ICER为1629019美元。

关键数值与推荐

  • PFS分析:联合组费用494983美元 vs 单药组132950美元,联合组较单药组高362033美元。
  • ICER为每PFS生命年2129606美元,ICUR为每PFS质量调整生命年2262706美元。
  • 概率敏感性分析:ICER为每PFS生命年1481208美元,ICUR为每PFS质量调整生命年1683191美元。
  • ORR分析:联合组费用474904美元 vs 单药组132810美元,差值342094美元,每1例额外患者达到客观缓解的ICER为1629019美元。
  • 亚组分析:每1例额外患者达到客观缓解的ICER范围为1069044至17104700美元。

临床怎么用

  • 原文结论指出,联合治疗在人群层面相对伊匹木单抗单药不提供经济上有利的治疗选择,但不应排除对该方案可能适用的个体患者进行治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: A phase 2 trial comparing talimogene laherparepvec plus ipilimumab vs ipilimumab monotherapy in patients with advanced unresectable melanoma found no differential benefit in progression-free survival (PFS) but noted objective response rates (ORRs) of 38.8% (38 of 98 patients) vs 18.0% (18 of 100 patients), respectively. OBJECTIVE: To perform an economic evaluation of talimogene laherparepvec plus ipilimumab combination therapy vs ipilimumab monotherapy. DESIGN, SETTING, AND PARTICIPANTS: For PFS, cost-effectiveness and cost-utility analyses using a 2-state Markov model (PFS vs progression or death) was performed. For ORRs, cost-effectiveness analysis of the incremental cost of 1 additional patient achieving objective response was performed. In this setting based on a US payer perspective (2017 US dollars), participants were patients with advanced unresectable melanoma. MAIN OUTCOMES AND MEASURES: The PFS life-years and PFS quality-adjusted life-years were determined, and the associated incremental cost-effectiveness ratios (ICERs) and incremental cost-utility ratios (ICURs) were estimated. Also estimated was the ICER per 1 additional patient (out of 100 treated patients) achieving objective response. Base-case analyses were validated by sensitivity analyses. RESULTS: In PFS analyses, the cost of talimogene laherparepvec plus ipilimumab ($494 983) exceeded the cost of ipilimumab monotherapy ($132 950) by $362 033. The ICER was $2 129 606 per PFS life-years, and the ICUR was $2 262 706 per PFS quality-adjusted life-year gained. Probabilistic sensitivity analyses yielded an ICER of $1 481 208 per PFS life-year gained and an ICUR of $1 683 191 per PFS quality-adjusted life-year gained. In 1-way sensitivity analyses, the PFS hazard ratio and the utility of response were the most influential parameters. Talimogene laherparepvec plus ipilimumab has a 50% likelihood of being cost-effective at a willingness-to-pay threshold of $1 683 191 per PFS quality-adjusted life-year gained. In ORR analyses, talimogene laherparepvec plus ipilimumab ($474 904) vs ipilimumab alone ($132 810), a $342 094 difference, yielded an ICER of $1 629 019 per additional patient achieving objective response. In subgroup analyses by disease stage and BRAFV600E mutation status, ICERs ranged from $1 069 044 to $17 104 700 per 1 additional patient achieving objective response. CONCLUSIONS AND RELEVANCE: The cost to gain 1 additional progression-free quality-adjusted life-year, 1 additional progression-free life-year, or to have 1 additional patient attain objective response is about $1.6 million. This amount may be beyond what payers typically are willing to pay. Combination therapy of talimogene laherparepvec plus ipilimumab does not offer an economically beneficial treatment option relative to ipilimumab monotherapy at the population level. This should not preclude treatment for individual patients for whom this regimen may be indicated.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Almutairi AR, Alkhatib NS, Oh M, et al. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma. JAMA Dermatol. 2019. PMID: 30477000. doi:10.1001/jamadermatol.2018.3958

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。